DEF 14A: Utah Medical Products, Inc. Seeks Stockholder Approval for Director Re-election, Accounting Firm Ratification, and Executive Compensation Program

Utah Medical Products, Inc. is holding its annual stockholder meeting on May 3, 2024, to vote on the re-election of two directors, ratify the selection of its accounting firm, and conduct an advisory vote on executive compensation.

Summary

• Utah Medical Products, Inc. (UTMD) is holding its Annual Meeting of Stockholders on May 3, 2024.
• The meeting will address the re-election of Kevin L. Cornwell and Paul O. Richins as directors for terms expiring at the 2027 Annual Meeting.
• Stockholders will also vote to ratify the selection of Haynie & Company as the company's independent public accounting firm for the year ending December 31, 2024.
• An advisory vote on the company's executive compensation program will also be held.
• The Board of Directors recommends voting FOR the nominated directors, FOR ratification of Haynie & Company, and in support of the executive compensation program.
• Only stockholders of record as of March 1, 2024, are entitled to vote.
• The proxy statement was first furnished to stockholders on approximately April 12, 2024.
• Executive officers and directors holding approximately 6.5% of the outstanding stock intend to vote in favor of the proposals.
• The company's long-term key financial objective is a 15% annually compounded rate of increase in EPS and average ROE prior to payment of cash dividends.
• As of the end of 2023, the Company has actually achieved a 13% annually compounded rate of increase in EPS and an average annual ROE (prior to payment of stockholder dividends) of 26% over the thirty-seven years since 1986, UTMDs first year of profitability since becoming a publicly-traded company.

Sentiment

Score: 7

Explanation: The document is generally positive, focusing on governance matters and recommending votes in favor of management's proposals. While there are some mentions of challenges like supply chain disruptions and litigation expenses, the overall tone is optimistic and forward-looking.

Positives

• The Board of Directors is recommending stockholders vote in favor of all proposals.
• Executive officers and directors holding approximately 6.5% of the outstanding stock intend to vote in favor of the proposals.
• The company has a clawback policy in place for executive incentive compensation.
• The company has achieved a 13% annually compounded rate of increase in EPS and an average annual ROE (prior to payment of stockholder dividends) of 26% over the thirty-seven years since 1986.

Negatives

• Brian Koopman, Principal Financial Officer, did not timely file one report on Form 4, which was due on October 31, 2023, and was filed on December 26, 2023.
• In 2023, UTMD exceeded its beginning of year objectives for sales, net profits and EPS, but fell short on gross profits due to continued inflation and supply chain disruption, and operating profits due to unforeseen litigation expenses.

Risks

• The performance each year may vary according to global economic conditions, government restrictions on medical procedures, competitive environment, life cycle of products, new product development, manufacturing costs and other factors.
• The company mentions unforeseen litigation expenses impacted operating profits in 2023.

Future Outlook

The company aims to enhance long-term profitability, EPS growth, and return on stockholders' equity.

Management Comments

• UTMD has always maintained an open invitation for stockholders to call management directly with questions and/or concerns, AT ANY TIME.
• The Board of Directors considers this policy highly contributory to growth in future stockholder value.

Industry Context

The document includes a stock performance chart comparing UTMD's performance against the NASDAQ Composite Total Return and the NASDAQ ICB: 4537 Medical Supplies index, providing context within the medical supplies subsector.

Comparison to Industry Standards

• The document compares UTMD's stock performance against the NASDAQ Composite Total Return and the NASDAQ ICB: 4537 Medical Supplies index.
• The company uses surveys of similar companies selected from among the companies with which UTMDs stock is compared in the Stock Performance Chart, based on variations in industry type, geographic location, size, and profitability as the Committee deems appropriate.

Stakeholder Impact

• The document outlines proposals directly impacting shareholders through voting rights and decisions on director elections, accounting firm ratification, and executive compensation.
• Employees are impacted through the executive compensation program and the company's overall compensation policies.
• The selection of an independent accounting firm impacts the reliability of financial reporting for all stakeholders.

Next Steps

• Stockholders are encouraged to complete and return their proxies promptly.
• The Board of Directors and Compensation and Benefits Committee will review the voting results and consider feedback in future decisions about executive compensation.
• The Governance and Nominating Committee will consider nominees recommended by stockholders for future director elections.

Key Dates

Keywords

proxy statement, annual meeting, directors, executive compensation, accounting firm, stockholders, UTMD, governance